Pierre Fabre Group
A Bioprocess Expert in Antibody-Drug Conjugates (ADC) and next generation conjugates for CMC develops and optimizes bioprocesses for ADCs, ensuring robust, compliant manufacturing processes and high-quality clinical and commercial supplies.
Founded in 1962 by Mr. Pierre Fabre, Pierre Fabre is an international French pharmaceutical and dermo-cosmetic group owned by a public benefit foundation and its employees.
Naos appoints Frédéric Ennabli, former Pierre Fabre executive, as board chairman
Sep 29, 2025
Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets
Oct 10, 2022
Pierre Fabre Has Acquired Dermocosmetics Brand Même
May 9, 2023
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Pierre Fabre Group.
Right around the average for this role
Eric Ducournau Named Chief Executive Officer of the Pierre Fabre Group
May 31, 2018
Scientist III, Bioconjugation (ADC) Process Development
Exelixis
Director, CMC – Biologics & ADC
Pathos
Scientist III - Bioconjugation (ADC) Process Development
Exelixis
Future Opportunities, Join our talent community for Sr Scientist II/Principal Scientist in Bioprocess Engineering
AbbVie
Scientist – Protein Engineering – Organic Chemist: ADC Research & Development
Amgen
Future Opportunities, Join our talent community for Sr Scientist II/Principal Scientist in Bioprocess Engineering
AbbVie